Advertisements


Will Positive Phase III Data For Roche"s Anti IL-6 Antibody Spell Trouble For Alexion"s C5 Inhibitor In NMOSD?

Will Positive Phase III Data For Roche"s Anti IL-6 Antibody Spell Trouble For Alexion"s C5 Inhibitor In NMOSD?.....»»

Category: topSource: seekingalphaJan 11th, 2019

Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data

Omeros Corporation (NASDAQ: OMER) shares are seeing buying interest Thursday following a clinical update on its lead human monoclonal antibody OMS721, which is being evaluated for IgA nephropathy. read more.....»»

Category: blogSource: benzingaJan 17th, 2019

Alexion to present "positive" Phase 3 data for ALXN1210 at ASH meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 3rd, 2018

Roche Announces Positive Data on Breast Cancer Drug Kadcyla

Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal. Roche RHHBY announced encouraging results from a phase III st.....»»

Category: smallbizSource: nytOct 16th, 2018

Pfizer"s Skin Disease Candidates Positive in Mid-Stage Study

Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study. Pfizer Inc. PFE announced positive top-line data from a phase IIa.....»»

Category: personnelSource: nytSep 17th, 2018

resTORbio Spikes Higher Following Positive Phase 2 Data

resTORbio, Inc. (NASDAQ: TORC) announced Wednesday its TORC1 inhibitor treatment demonstrated targeted improvements in a Phase 2a clinical trial. read more.....»»

Category: blogSource: benzingaJul 11th, 2018

Roche (RHHBY) Announces Positive Data on Hemophilia Drug

Roche (RHHBY) announces positive data from two phase III studies on hemophilia drug Hemlibra which has further strengthened its hemophilia portfolio. Roche RHHBY announced full results from the phase III study, HAVEN 3, evaluating haemo.....»»

Category: dealsSource: nytMay 21st, 2018

Alexion announces publication of REGAIN Phase 3 interim data in Muscle & Nerve

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 8th, 2019

AC Immune announces anti-tau monoclonal antibody entering second Phase 2 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 20th, 2019

Moderna announces positive phase 1 data for hMPV/PIV3 combination vaccine

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 12th, 2019

Alexion reports "positive" results from Phase 3 study of ULTOMIRIS

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 28th, 2019

Ultragenyx stock up 2.9% after safety and efficacy trial reaffirms Phase 2 data

Shares of Ultragenyx Pharmaceutical Inc. rose 2.9% in premarket trade Tuesday after the company announced positive results from a safety and efficacy study looking at a treatment for patients with lo.....»»

Category: topSource: marketwatchJan 22nd, 2019

Aslan announces "positive" data from Phase 1b/2 trial of varlitinib plus gem/cis

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 14th, 2019

Deciphera announces "positive" preliminary data from Phase 1 study with DCC-3014

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 2nd, 2019

Vertex"s (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint

Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy. .....»»

Category: personnelSource: nytDec 19th, 2018

Achillion reports positive interim data for ACH-4471 Phase 2 trials

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 17th, 2018

Wedbush "positive" on Idera"s Phase 2 study data

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 17th, 2018

Roche Announces Positive Data on Venclexta/Venclyxto at ASH

Roche (RHHBY) announces new Venclexta/Venclyxto data tha.....»»

Category: smallbizSource: nytDec 4th, 2018

Aslan Pharmaceuticals presents positive data from Phase 2a study of ASLAN003

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 2nd, 2018

Regeneron presents positive data at for REGN1979 CD20xCD3 bispecific antibody

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 2nd, 2018

Karyopharm reports positive top-line Phase 2b SADAL data for Selinexor

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 2nd, 2018